Skip to main content
Detectable Circulating Tumor DNA 28 Days after the CD19 CAR T-Cell Therapy, Axicabtagene Ciloleucel, Is Associated with Poor Outcomes in Patients with Diffuse Large B-Cell Lymphoma Frank, M. J., Hossain, N., Bukhari, A., Dean, E., Spiegel, J. Y., Claire, G. K., Kirsch, I. M., Jacob, A. P., Mullins, C. D., Lee, L., Kong, K. A., Craig, J., Mackall, C. L., Rapoport, A. P., Dahiya, S., Locke, F. L., Miklos, D. B. AMER SOC HEMATOLOGY. 2019

View details for DOI 10.1182/blood-2019-132057

View details for Web of Science ID 000518218500905